skip to main content
Close Icon We use cookies to improve your website experience.  To learn about our use of cookies and how you can manage your cookie settings, please see our Cookie Policy.  By continuing to use the website, you consent to our use of cookies.
Global Search Configuration


Biomedtracker | Pharma intelligence

Biomedtracker(バイオメドトラッカー)では、アメリカの医薬品開発プロセスの動きを2003年以降独自に分析しています。弊社アナリストチームが下記に挙げる代表的なイベントと、それらによるインパクトを発生と同時に分析&評価し、アメリカ食品医薬品局(FDA)の承認確率(LOA: Likelihood of Approval)で提示します。そうすることで、医薬品の開発動向をいち早く正確に把握できるデータベースがBiomedtrackerです。


  • 臨床試験の開始や結果報告
  • 学会やカンファレンスにおける発表
  • ライセンス、M&A、提携に関する活動
  • 企業発表(プレスリリース、収支報告、投資家向け情報)
  • 薬事行政の動向、など




アナリストが参加した学会のレポートを発行します(例: JP Morgan, ASCO, ASH, AAN, ATSなど)。お客様が参加することができなかった海外の学会に関する情報を収集できます。また、アメリカ食品医薬品局(FDA)諮問委員会での評価・投票結果やKOL(Key Opinion Leader)インタビュー、弊社が発行する様々なレポートにもアクセスできます。

Datamonitor Healthcareとの併用が効果的です
開発中医薬品をリアルタイムで追跡するBiomedtrackerは、医薬品の市場調査レポートライブラリーである姉妹サービスDatamonitor Healthcareとの併用が効果的です。ぜひ合わせてご検討ください。





  • Biomedtracker: 開発中医薬品をFDA承認確率で評価, Datamonitor Healthcare: 医療...

    December 2018 National Influenza Week

    29 Nov 2018

    3 – 9 December is National Influenza Vaccination Week, a national awareness week focused on highlighting the importance of influenza vaccination. In this free KOL Insight Interview excerpt from Datamonitor Healthcare, read what key opinion leaders from the UK and US in Infectious Diseases have to say about current efforts to combat influenza with seasonal influenza vaccines:

    Topic influenza-virus infectious-diseases

  • Biomedtracker: 開発中医薬品をFDA承認確率で評価

    Q4 Outlook Webinar - Key Catalysts and their Impact on Pharma Markets

    19 Nov 2018

    Understand important upcoming milestones that will impact the likelihood of drug approval or future sales potential for key therapies during a free webinar from Informa Pharma Intelligence, "Q4 Outlook Webinar - Key Catalysts and their Impact on Pharma Markets".

    Topic drug-development-landscape

  • Biomedtracker: 開発中医薬品をFDA承認確率で評価

    Biomedtracker Q4 2018 Outlook Report

    19 Oct 2018

    Find out what’s in store for the remainder of 2018 with your copy of the Biomedtracker Q4 2018 Outlook Report Extract. This essential analysis of expected Q4 catalysts for 27 drugs is now available to you – for free. Drawn from the full report of the same name, this vital resource explores the likelihood of phase/PDUFA review success and overall Likelihood of Approval (LOA) based on a drug’s phase, drug class, and disease group.

    Topic drug-development-landscape

  • Biomedtracker: 開発中医薬品をFDA承認確率で評価

    Pharma Partnering Trends Revealed Whitepaper

    12 Oct 2018

    Make the most of BIO-Europe 2018 with essential partnering information from Informa Pharma Intelligence. Our insightful whitepaper, Pharma Partnering Trends Revealed: 2018 Edition, contains critical information on the landscape for biotech partnerships, and is now available for you to download – free.

  • Biomedtracker

    Biomedtracker Q3 2018 Outlook Infographic

    22 Aug 2018

    For a look at the outcomes for predicted Q2 2018 catalysts, we invite you to download a free copy of the data-rich Catalyst Roundup infographic from Biomedtracker. This informative graphic takes a look at the outcomes for two major catalysts featured in Biomedtracker’s insightful Q2 2018 Outlook Report.

    Topic drug-development-landscape

  • Biomedtracker

    Biomedtracker 2018 Early Outlook Report

    15 Aug 2018

    What's on the horizon for pharma in 2018? Find out with Biomedtracker's Early 2018 Outlook Report extract. Download free extracts from this essential report, which investigates the catalysts expected to occur in the first part of the year for 21 different drugs.

    Topic drug-development-landscape

  • Biomedtracker

    Biomedtracker Q3 2018 Outlook Report Extract

    15 Aug 2018

    Download an extract of the data-rich resource: Biomedtracker’s Q3 2018 Outlook Report. This latest installment in Biomedtracker’s ongoing quarterly reports contains expected drug catalyst predictions, important clinical and regulatory milestones, and Large Impact catalysts for the upcoming quarter. 

    Topic drug-development-landscape

  • Citeline, Scrip:世界の医薬品産業ニュースサービス, Biomedtracker, Datamonitor...

    ASCO Essentials Webinar 2018 Recording

    29 May 2018

    Just in time for your 2018 ASCO Annual Meeting planning, join analysts from Datamonitor Healthcare, Biomedtracker, Citeline, Scrip, and Pink Sheet for their expert opinions on what you need to know to get the most from the meeting. Let our experts present their top picks from the thousands of abstracts being presented at ASCO.

    Topic Clinical trials

  • Biomedtracker

    Q2 Outlook Report Extract

    10 May 2018

    Get a reliable and accurate view of what’s on the horizon for pharma in the coming quarter. The Biomedtracker Q2 2018 Outlook Report includes essential information, including each drug’s likelihood of phase/PDUFA review success and overall Likelihood of Approval (LOA) given their particular phase, drug class, and disease group.

    Topic drug-review

  • Datamonitor Healthcare, Biomedtracker

    Pharma Intelligence Commercial Solution: Beat Your Competition

    05 Apr 2018

    To beat your competition, turn to the combined power of Biomedtracker and Datamonitor Healthcare for the most reliable and timely information in the industry.

    Topic drug-review

  • Biomedtracker

    Biomedtracker 2018 Early Outlook Infographic

    05 Apr 2018

    For a look at the outcome of two catalysts featured in Biomedtracker’s Q4 2017 Outlook Report, download the Catalyst Roundup: A Review of Select Catalysts from Last Quarter’s Outlook Report.

    Topic drug-development-landscape

  • Biomedtracker

    2018 JP Morgan Healthcare Conference Review

    05 Apr 2018

    Don't miss out on this comprehensive review of all the presentations from the conference, complied by our analysts, with key points and expert insight, for you to download, for free. A full list of events and catalysts that were announced or updated during the conference is included in this report.

    Topic Strategy

  • Biomedtracker

    Q4 outlook report 2017

    01 Nov 2017

    Catalyst Roundup: A review of select catalysts from last quarter's outlook report

  • Biomedtracker

    BMT Q4 Outlook Report

    27 Oct 2017

    In this report, we cover catalysts from 21 drugs expected to occur in Q4 2017. For each drug, the likelihood of Phase/PDUFA review success and overall Likelihood of Approval (LOA) given their particular phase, drug class, and disease group are provided.

    Topic alzheimers cancer drug-approval

  • Biomedtracker

    Outcomes of Biomedtracker's Large Impact Catalysts from the Early 2017 Outlook Report

    10 Aug 2017

    This free infographic comes to you from Biomedtracker, part of the Informa suite of Pharma Intelligence tools.

    Topic company-analysis



Patricia Reilly

Management, VP, Intelligence Alliances and Product Unification
Patricia Reilly

Patricia specializes in

  • CNS
  • Immunology and Inflammation
  • Oncology

+27 year(s) experience


Gail Parziale

Management, ​Head of Intelligence Editorial Operations
Gail Parziale

Gail specializes in

  • Commercial Strategy
  • Clinical Trials

+22 year(s) experience


Rachel Meighan-Mantha

Analyst, Principal Analyst
Rachel Meighan-Mantha

Rachel specializes in

  • Oncology
  • Clinical Trials

+22 year(s) experience




電話:+81 (0)3 6273 4260